{
  "id": 13621777,
  "title": "Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares",
  "url": "https://urgent.news/2026/10/11/vaxcyte-evp-coo-jim-wassil-sells-1-56m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T02:31:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/vaxcyte-evp-coo-jim-wassil-sells-156m-in-shares-93CH-4942432"
  },
  "original_language": "en",
  "account": null,
  "summary": "Vaxcyte EVP and COO Jim Wassil sold 18,000 shares of the company's common stock on October 5, 2026, at a price of $86.74 per share, totaling $1,561,320. This sale, executed pursuant to a Rule 10b5-1 trading plan, followed by the acquisition of the same amount of shares through the exercise of stock options, resulted in Wassil holding 145,435 shares of Vaxcyte, Inc. common stock. Analysts have noted that the stock appears overvalued at current levels, with some raising price targets and others maintaining Buy ratings, while acknowledging the successful outcome of Vaxcyte's OPUS-1 trial for its VAX-31 vaccine candidate.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}